Loading clinical trials...

A Study for Patients With Multiple Sclerosis | Clinical Trials | Clareo Health

TERMINATEDPHASE2/PHASE3

A Study for Patients With Multiple Sclerosis

An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis

NCT00870155•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

To obtain additional safety data in subjects who have previously completed the MBP8298-01 study "A Double Blind Placebo Controlled Multi-Centre to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Multiple Sclerosis" Dirucotide is generic name for MBP8298.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Subjects participating in this study must have completed treatment and all required evaluations in the previous MBP8298-01 study "A Double Blind Placebo Controlled Multi-Centre Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis",
•2. Subject must be able and willing to give meaningful, written informed consent prior to participation in the trial in accordance with regulatory requirements,
•3. In the Investigator's opinion, subjects must be reliable, compliant and agree to cooperate with all trial evaluations.

Exclusion Criteria

•1. Use of any concomitant disease modifying therapy for Multiple Sclerosis e.g. ß-interferon, glatiramer acetate or mitoxantrone, cyclophosphamide, methotrexate, azathioprine, or any other immuno-modulating (e.g. IVIG) or immunosuppressive drugs including recombinant or non-recombinant cytokines.
•2. Any medical, psychiatric or other condition that could result in a subject not being able to give fully informed consent, or to comply with the protocol requirements.
•3. Any other condition that, in the Investigator's opinion, makes the subject unsuitable for participation in the study.
•4. Females who are breast feeding, pregnant or not using a medically approved method of contraception regularly.

Locations (10)

St. Michaels Hospital

Toronto, Ontario, Canada

Copenhagen University Hospital

Copenhagen, Denmark

West Tallinn Central Hospital

Tallinn, Estonia

Terveystalo Turku Kuvantaminen

Turku, Finland

Heinrich Heine Universitaets

Düsseldorf, North Rhine-Westphalia, Germany

Vecmilgravis Hospital

Riga, Latvia

Maaslandziekenhuis

Sittard, Netherlands

Hospital Duran I Reynals

Barcelona, Spain

Karolinska Universitetssjukhus

Stockholm, Sweden

Walton Hospital

Liverpool, United Kingdom

Key Dates

Start Date

February 1, 2007

Primary Completion Date

September 1, 2009

Completion Date

September 1, 2009

Last Updated

September 9, 2010

Enrollment

546

ESTIMATED participants

Conditions

Secondary Progressive Multiple Sclerosis

Interventions

dirucotide

DRUG

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGPHASE3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628

Relapsing Multiple SclerosisRelapsing Remitting Multiple Sclerosis+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 9, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study for Patients With Multiple Sclerosis

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Metformin Treatment in Progressive Multiple Sclerosis

Multiple Sclerosis-Simvastatin Trial 2

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)